Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

Documenti analoghi

• Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders
  di: Herold, Kevan C., et al.
  Pubblicazione: (2013)
• Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
  di: Perdigoto, Ana Luisa, et al.
  Pubblicazione: (2018)
• Changes in T cell subsets identify responders to FcR non-binding anti-CD3 mAb (teplizumab) in patients with Type 1 diabetes
  di: Tooley, James E, et al.
  Pubblicazione: (2015)
• TCR stimulation with modified anti-CD3 mAb expands CD8(+) T cell population and induces CD8(+)CD25(+) Tregs
  di: Bisikirska, Brygida, et al.
  Pubblicazione: (2005)
• An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
  di: Herold, Kevan C., et al.
  Pubblicazione: (2019)